MediWound (MDWD) EBITDA (2013 - 2026)

MediWound has reported EBITDA for 14 years, with the latest figure at -$9.5 million in Q2 2026.

• On a quarterly basis, EBITDA fell 65.47% year-over-year to -$9.5 million in Q2 2026; TTM through Jun 2026 was -$28.2 million, a 54.59% decrease from a year earlier, with the FY2025 full-year figure at -$20.3 million, down 37.6% from the prior year.
• EBITDA was -$9.5 million for Q2 2026 at MediWound, down from -$7.0 million in the prior quarter.
• The five-year high for EBITDA was $3.4 million in Q4 2022, with the low at -$9.5 million in Q2 2026.
• Average EBITDA over 5 years is -$4.0 million, with a median of -$3.8 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: EBITDA jumped 219.93% in 2022, then tumbled 194.54% in 2023.
• Over 5 years, EBITDA stood at $3.4 million in 2022, then sank by 194.54% to -$3.2 million in 2023, then tumbled by 50.26% to -$4.9 million in 2024, then plunged by 32.92% to -$6.5 million in 2025, then sank by 46.3% to -$9.5 million in 2026.
• The last three EBITDA figures came in at -$9.5 million (Q2 2026), -$7.0 million (Q1 2026), and -$6.5 million (Q4 2025), per Business Quant data.